Close
Close

Peptide Post-Translational Modification (PTM) Analysis Service by Yeast Display

Services Workflow Platform Advantages Related Services FAQ

Yeast Display Enabled Analysis of Peptide PTMs

Post‑translational modifications (PTMs), including phosphorylation and glycosylation, fundamentally reshape peptide function. However, producing homogeneous, site‑specific modified peptides remains challenging. Creative Biolabs utilizes yeast‑derived endogenous or engineered modifying enzymes (e.g., kinases, glycosyltransferases) to display PTM peptides directly on yeast cell surfaces. This provides researchers with a powerful discovery tool to identify PTM‑specific antibodies, biosensors and binding proteins, free from heterogeneity‑related artifacts typical of chemical synthesis.

Explore Related Solutions

Fig. 1 Observation (Creative Biolabs AI)

Yeast Display based MHC-Peptide Discovery

Identify immunogenic peptide candidates for vaccine development or TCR‑directed therapeutics.

Fig. 2 Petridish (Creative Biolabs AI)

Yeast Display‑based Evolutionary Optimization of Peptide

Improve affinity, stability, or selectivity of existing peptide leads through iterative mutagenesis and selection.

Fig. 3 Setting (Creative Biolabs AI)

Yeast Display based Ligand‑Receptor Interaction

Map binding interfaces and discover competitive peptide ligands.

Fig. 4 Robot (Creative Biolabs AI)

Yeast Display based AI-Driven Peptide Library Design & Screening

Combine machine‑learning library prediction with empirical yeast display screening for accelerated hit discovery.

Request a Quote →

From Your Target to Delivered Data: How We Operate

Starting Materials
Fig.5 Materials (Creative Biolabs AI)
  • Target peptide sequence information
  • Desired PTM type (e.g., phosphorylation, N-/O‑glycosylation)
  • Intended application (antibody screening, binder discovery)

Fig.6 Genetic Shield (Creative Biolabs AI)

Yeast strain selection or engineering for PTM activity

Fig. 7 Quick Click (Creative Biolabs AI)

Construction of yeast display peptide library

Fig. 8 Premium Link (Creative Biolabs AI)

Induction of modification under optimized culture conditions

Fig. 9 Data Panel (Creative Biolabs AI)

Flow cytometry‑based screening against target probes

Fig. 10 Doc Check (Creative Biolabs AI)

Sequence recovery and validation

Deliverables

Fig. 11 Order Fulfill (Creative Biolabs AI)

  • Enriched peptide clone sequences
  • PTM fidelity assessment data
  • Binding profiles against query antibodies or receptors
  • Purified plasmid constructs upon request
Estimated Timeline

Fig. 12 Fast Turnaround (Creative Biolabs AI)

Project duration depends on library complexity and PTM type; typical timelines range from several weeks to a few months, with milestone reports provided throughout.

→ Learn More About Our Process

Platform – Fueling Your Path to Success

The proprietary yeast display platform enables stable, high‑density surface expression of peptide libraries with controlled PTM patterns. Aga1/Aga2 fusion design ensures uniform presentation, while fluorescence‑activated cell sorting (FACS) allows quantitative screening of millions of variants. Access the full technical specifications and validation data on the dedicated platform page.
Yeast Display Platform - Creative Biolabs

→ Evaluate Your Target with Our Platform

What Makes Our PTM Analysis Different

Fig. 13 Gene Cycle (Creative Biolabs AI)

Site‑Specific Native Modifications
Unlike chemical synthesis, which often generates mixtures or requires protecting‑group chemistry for glycans, this platform presents complex PTM structures (e.g., high‑mannose, O‑GlcNAc) more natively. Yeast's endogenous machinery installs modifications at designated residues with high positional fidelity.

Fig. 14 Tech Gene (Creative Biolabs AI)

Integrated Functional Validation
Screening directly on yeast surface links PTM presentation to binding readouts. Biosensors or antibodies recognizing specific modification states (e.g., phospho‑serine vs. unmodified) are identified in the same workflow without separate conjugation steps.

Fig. 15 Growth Chart (Creative Biolabs AI)

Therapy‑Diagnostics Empowerment
PTM‑specific antibody development for immuno‑oncology or neurodegeneration; Deciphering disease‑related aberrant glycosylation or phosphorylation pathways; Identifying synthetic biology tools that read or write PTM codes.

All client data remains strictly confidential. No proprietary figures or project‑specific results are disclosed without permission.

→ Contact Our Experts

Broader Services for Your Reference

Explore our complete suite of yeast display technology offerings

Yeast Display Library Construction

Custom library design and construction covering diverse peptide scaffolds and diversities.

Yeast Display Library Screening

High‑throughput FACS‑based screening against soluble, membrane‑bound, or complex antigen targets.

Yeast Display-Based Antibody Affinity Maturation

Rationally improve antibody lead affinity and biophysical properties.

Yeast Display-Based T Cell Receptor Engineering

Enhance TCR specificity, affinity, or stability for cell therapy applications.

Human Monoclonal Antibody Identification

Full human antibody discovery from naïve or immune yeast display libraries.

Yeast Display based Antibody Discovery

End‑to‑end antibody hit generation against challenging targets.

Yeast Display based Protein Optimization and Engineering

Improve expression, stability, or activity of protein leads through directed evolution.

→ Get a tailored proposal for your target

Your All Questions Answered

  1. How is PTM fidelity validated on the yeast surface?

    PTM presence and site specificity are confirmed via modification‑specific antibodies or lectins in flow cytometry, and optionally by MS‑based peptide sequencing after elution. Unmodified controls are run in parallel.

  2. What is the typical library diversity for a PTM‑focused peptide screen?

    Library size depends on the peptide length and modification complexity. Standard diversities range from 107 to 108 unique variants, sufficient for most binder discovery campaigns.

  3. Can the platform handle long peptides or mini‑proteins with multiple PTMs?

    Yes. Peptides up to ~100 amino acids are routinely displayed. Multiple PTMs (e.g., dual phosphorylation or glycosylation + phosphorylation) can be introduced using engineered yeast strains expressing orthogonal modification enzymes.

  4. What data deliverables are provided at project completion?

    A final report includes enrichment plots, sequence lists of top clones, binding validation histograms, PTM fidelity assessment, and a technical methods summary. Raw FACS data files are available upon request.

  5. How is confidentiality handled for proprietary target sequences?

    All project information is protected under a standard mutual NDA. Yeast strains and sequences are destroyed or returned per client instruction. No client data is used for internal R&D without explicit written consent.

  6. What turnaround time can be expected for an initial PTM screening project?

    Pilot studies with a single PTM type and moderate library size typically complete within 12-16 weeks. Complex projects involving multi‑step glycosylation or custom enzyme engineering are scoped during the proposal phase.

Get a tailored proposal for your target (links to /contact or quote form)


All listed services and products are For Research Use Only. Do Not use in any diagnostic or therapeutic applications.

Related Sections
Online Inquiry
CONTACT US
USA:
Europe:
Germany:
Call us at:
USA:
UK:
Germany:
Fax:
Email:
Our customer service representatives are available 24 hours a day, 7 days a week. Contact Us
© 2026 Creative Biolabs. | Contact Us